Oryzon Genomics S.A. (ORY.MC)
EUR 1.59
(-3.98%)
EUR 1.59
(-3.98%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 106.9 Million EUR | 3.09% |
| 2022 | 103.69 Million EUR | 8.72% |
| 2021 | 95.38 Million EUR | 1.36% |
| 2020 | 94.1 Million EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 107.78 Million USD | -6.18% |
| 2024 Q3 | 122.66 Million EUR | 10.83% |
| 2024 Q2 | 110.67 Million EUR | 10.34% |
| 2023 FY | 106.9 Million EUR | 3.09% |
| 2023 Q1 | 103.28 Million EUR | 0.0% |
| 2023 Q2 | 104.63 Million EUR | 1.31% |
| 2023 Q4 | 106.9 Million EUR | 4.57% |
| 2023 Q3 | 102.23 Million EUR | -2.3% |
| 2022 Q4 | - EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -626.717% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 67.315% |
| Adocia SA | 24.95 Million EUR | -328.354% |
| Aelis Farma SA | 26.28 Million EUR | -306.758% |
| Biophytis S.A. | 11.93 Million EUR | -795.611% |
| Advicenne S.A. | 12.4 Million EUR | -761.611% |
| genOway Société anonyme | 31.84 Million EUR | -235.717% |
| IntegraGen SA | 8 Million EUR | -1236.193% |
| Medesis Pharma S.A. | 1.92 Million EUR | -5449.405% |
| Neovacs S.A. | 47.53 Million EUR | -124.894% |
| NFL Biosciences SA | 3.97 Million EUR | -2592.273% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -616.829% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -2753.127% |
| Sensorion SA | 46.49 Million EUR | -129.922% |
| Theranexus Société Anonyme | 7.23 Million EUR | -1376.983% |
| TME Pharma N.V. | 2.49 Million EUR | -4191.455% |
| Valbiotis SA | 33.24 Million EUR | -221.524% |
| TheraVet SA | 7.53 Million EUR | -1318.867% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -203.056% |
| argenx SE | 4.11 Billion EUR | 97.4% |
| BioSenic S.A. | 9.55 Million EUR | -1018.319% |
| Celyad Oncology SA | 16.28 Million EUR | -556.554% |
| DBV Technologies S.A. | 165.65 Million USD | 35.467% |
| Galapagos NV | 4.35 Billion EUR | 97.547% |
| Genfit S.A. | 173.87 Million EUR | 38.518% |
| GeNeuro SA | 6.31 Million EUR | -1593.36% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -124.199% |
| Innate Pharma S.A. | 184.19 Million EUR | 41.963% |
| Inventiva S.A. | 69.13 Million EUR | -54.616% |
| MaaT Pharma SA | 42.93 Million EUR | -149.005% |
| MedinCell S.A. | 36.94 Million EUR | -189.326% |
| Nanobiotix S.A. | 93.89 Million EUR | -13.848% |
| Onward Medical N.V. | 43.62 Million EUR | -145.021% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -30.525% |
| Oxurion NV | 6.55 Million EUR | -1532.063% |
| Pharming Group N.V. | 426.33 Million EUR | 74.926% |
| Poxel S.A. | 4.82 Million EUR | -2116.466% |
| GenSight Biologics S.A. | 9.08 Million EUR | -1076.407% |
| Transgene SA | 45.21 Million EUR | -136.416% |
| Financière de Tubize SA | 1.92 Billion EUR | 94.433% |
| UCB SA | 15.53 Billion EUR | 99.312% |
| Valneva SE | 469.39 Million EUR | 77.226% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -246.752% |